Impact of clinical features of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients on osimertinib efficacy

Chiara Lazzari, Vanesa Gregorc, Mariacarmela Santarpia


Lung cancer remains the first cause of cancer-related deaths worldwide (1). Thanks to technological advances, the molecular landscape of non-small cell lung cancer (NSCLC) has evolved, with the emergence of different subtypes of NSCLC tumors (2), some of which amenable of targeted inhibition. Clinical practice has shifted towards the era of precision medicine, where molecular classification has become part of routine cancer care, enabling treatment to be matched with patient’s tumor genomic profile. In many tumor types, including lung cancer, these efforts have been translated into significantly longer patients’ survival (3).